BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C. Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals (Basel) 2021;14:738. [PMID: 34451835 DOI: 10.3390/ph14080738] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Singh DD, Han I, Choi EH, Yadav DK. A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors. Curr Issues Mol Biol 2023;45:400-33. [PMID: 36661514 DOI: 10.3390/cimb45010028] [Reference Citation Analysis]
2 Askr H, Elgeldawi E, Aboul Ella H, Elshaier YAMM, Gomaa MM, Hassanien AE. Deep learning in drug discovery: an integrative review and future challenges. Artif Intell Rev 2022. [DOI: 10.1007/s10462-022-10306-1] [Reference Citation Analysis]
3 Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol 2022;77:1161-97. [PMID: 35868584 DOI: 10.1016/j.jhep.2022.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
4 Malekinejad Z, Baghbanzadeh A, Nakhlband A, Baradaran B, Jafari S, Bagheri Y, Raei F, Montazersaheb S, Farahzadi R. Recent clinical findings on the role of kinase inhibitors in COVID-19 management. Life Sci 2022;306:120809. [PMID: 35841979 DOI: 10.1016/j.lfs.2022.120809] [Reference Citation Analysis]
5 Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022;39:2342-64. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Agut H. Antivirales (a excepción del virus de la inmunodeficiencia humana y la hepatitis). EMC - Tratado de Medicina 2022;26:1-10. [DOI: 10.1016/s1636-5410(22)46453-1] [Reference Citation Analysis]
7 Nag S, Baidya ATK, Mandal A, Mathew AT, Das B, Devi B, Kumar R. Deep learning tools for advancing drug discovery and development. 3 Biotech 2022;12:110. [PMID: 35433167 DOI: 10.1007/s13205-022-03165-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Levy G, Guglielmelli P, Langmuir P, Constantinescu S. JAK inhibitors and COVID-19. J Immunother Cancer 2022;10:e002838. [PMID: 35459733 DOI: 10.1136/jitc-2021-002838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Barilli A, Visigalli R, Ferrari F, Bianchi MG, Dall’asta V, Rotoli BM. Immune-Mediated Inflammatory Responses of Alveolar Epithelial Cells: Implications for COVID-19 Lung Pathology. Biomedicines 2022;10:618. [DOI: 10.3390/biomedicines10030618] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
10 . Baricitinib. Reactions Weekly 2022;1898:108-108. [DOI: 10.1007/s40278-022-11701-9] [Reference Citation Analysis]
11 Nappi F, Iervolino A, Avtaar Singh SS. Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. Biomedicines 2022;10:437. [DOI: 10.3390/biomedicines10020437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Shaker ME, Hendawy OM, El-Mesery M, Hazem SH. The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice. Int Immunopharmacol 2021;103:108463. [PMID: 34952468 DOI: 10.1016/j.intimp.2021.108463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ezeonwumelu IJ, Garcia-Vidal E, Ballana E. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections. Viruses 2021;13:2379. [PMID: 34960648 DOI: 10.3390/v13122379] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
14 Farahani M, Niknam Z, Mohammadi Amirabad L, Amiri-Dashatan N, Koushki M, Nemati M, Danesh Pouya F, Rezaei-Tavirani M, Rasmi Y, Tayebi L. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed Pharmacother 2022;145:112420. [PMID: 34801852 DOI: 10.1016/j.biopha.2021.112420] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
15 Lan SH, Wang CK, Chang SP, Lu LC, Hung SH, Lin WT. Janus kinase inhibitors for hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34743661 DOI: 10.1080/14787210.2022.2004120] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
16 Yadav DK, Singh DD, Han I, Kumar Y, Choi EH. Current Potential Therapeutic Approaches against SARS-CoV-2: A Review. Biomedicines 2021;9:1620. [PMID: 34829850 DOI: 10.3390/biomedicines9111620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Limen RY, Sedono R, Sugiarto A, Hariyanto TI. Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. Expert Rev Anti Infect Ther 2021;:1-10. [PMID: 34538216 DOI: 10.1080/14787210.2021.1982695] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Pires C. A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019. J Pers Med 2021;11:926. [PMID: 34575703 DOI: 10.3390/jpm11090926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]